引用次数
引用: 97,128
H-指数: 136
I10-指数 : 357
出版物: 680
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Yaohua Xue , Luciano Martelotto , Timour Baslan , Alberto Vides
Nature Medicine 23 ( 8) 929 -937
85
2017
18th IASLC World Conference on Lung Cancer
Ramaswamy Govindan , Greg J Riely , Shirish Gadgeel , Corey Langer
Management 7 00 -00
2017
EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL
Carlos G Ferreira , C Barrios , Alice T Shaw , Yuankai Shi
JOURNAL OF THORACIC ONCOLOGY 7 ( 7) S107 -S108
2012
Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling.
Mark G. Kris , Matthias A. Karajannis , Ingo Mellinghoff , Igor Gavrilovic
The Journal of Molecular Diagnostics 23 ( 6) 742 -752
2021
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Melissa L. Johnson , Greg J. Riely , Naiyer A. Rizvi , Christopher G. Azzoli
Journal of Thoracic Oncology 6 ( 6) 1128 -1131
60
2011
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Ken Takezawa , Valentina Pirazzoli , Maria E. Arcila , Caroline A. Nebhan
Cancer Discovery 2 ( 10) 922 -933
705
2012
Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer
Ken Takezawa , Mary Ann Melnick , Greg Riely , Mark Kris
Clinical Cancer Research 18
2012
Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers
Sandra Misale , Rona Yaeger , Riccardo Mezzadra , Jenna Sinopoli
2022
Clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS p. G12C-mutated metastatic non-small cell lung cancer (NSCLC) in the AACR Project GENIE database
Biagio Ricciuti , Chenguang Wang , Hira Rizvi , Jacklynn Egger
Cancer Research 81 ( 13_Supplement) 102 -102
2
2021
Induction Chemoradiotherapy Followed by Resection for Locally Advanced Masaoka Stage III and IVA Thymic Tumors. Commentary
James HUANG , Gregory J RIELY , Kenneth E ROSENZWEIG , Valerie W RUSCH
The Annals of thoracic surgery 85 ( 2)
2008
Intermolecular interactions of human placental protein 14
Gregory James Riely
Case Western Reserve University (Health Sciences)
1999
Acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer.
Gregory J. Riely , Marc Ladanyi , Marissa N. Balak , Allan R. Li
Cancer Research 66 1360 -1360
2006
Lung cancer in 'Never-smokers': molecular factors trump risk factors.
Gregory J. Riely
Oncology 24 ( 1)
4
2010
Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor
Mark G. Kris , Mark G. Kris , Gregory J. Riely , Gregory J. Riely
JCO Precision Oncology ( 5) 55 -64
2021
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
Mark G. Kris , Mark G. Kris , Gregory J. Riely , Gregory J. Riely
Clinical Cancer Research 27 ( 8) 2209 -2215
1
2021
KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.
Valerie W. Rusch , Gregory J. Riely , Prasad S. Adusumilli , Sandra Misale
Clinical Cancer Research 27 ( 9) 2604 -2612
2021
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
Mark G. Kris , Gregory J. Riely , Marc Ladanyi , Helena A. Yu
Clinical Cancer Research 27 ( 10) 2920 -2927
2021
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib
Mark G. Kris , Mark G. Kris , Gregory J. Riely , Gregory J. Riely
JCO Precision Oncology ( 5) 695 -700
2021
Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research.
Gregory J. Riely , Gregory J. Riely , Matthew D. Hellmann , Paul J. Sabbatini
Cancer Cell
2
2021
Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer.
Matthew S Alkaitis , Monica N Agrawal , Gregory J Riely , Pedram Razavi
JCO clinical cancer informatics 5 ( 5) 550 -560
2021